O'Neill Vincent 的 Form 4 申報
BioXcel Therapeutics, Inc.（BTAIQ），2024/10/3 申報
- 申報編號
- 0001104659-24-106060
- 申報時間
- 2024/10/3
- 交易日
- 2024/9/17-10/3
- 申報延遲
- 16 天遲報
- 10b5-1 計畫
- 有勾選
這份申報列了 2 筆非衍生性交易。公開市場賣出合計 $3,055.8。交易後 16 天才申報，超過 2 個營業日的期限。
申報人
一份 Form 4 可以有好幾位申報人，例如本人與他控制的基金。各交易表上顯示的是第一位。
| 申報人 | 與公司的關係 |
|---|---|
| O'Neill VincentCIK 0001672718 | 高階主管（見申報備註） |
非衍生性證券（表 I）
普通股等股票的取得與處分，每一列是申報上的一筆。
附註與備註
本站收錄交易價格引用的附註、修正申報（Form 4/A）的全部附註，以及申報的備註。其他附註，例如間接持有的方式、交易計畫的細節，請看 SEC EDGAR 上的原文。
- F1
The Issuer previously granted the Reporting Person an award of restricted stock units that would vest based on the Issuer's satisfaction of certain performance objectives and subject to the Reporting Person's continued service with the Issuer through October 1, 2024 (the "PSUs"). On September 17, 2024, the Compensation Committee of the Issuer's Board of Directors determined that performance conditions with respect to 21,250 PSUs had been satisfied and 21,250 shares of common stock became issuable to the Reporting Person on October 1, 2024.
表 I 有 1 筆交易的價格引用這則附註。
- F3
The price reported is a weighted average price. The securities were sold in multiple transactions at per share prices ranging from $0.5500 to $0.5501. The Reporting Person undertakes to provide upon request the Securities and Exchange Commission staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities sold at each separate price within the range set forth in this footnote.
表 I 有 1 筆交易的價格引用這則附註。
備註
Executive Vice President, Chief of Product Development and Medical Officer